Identifying the differences in mechanisms of mycophenolic acid controlling fucose content of glycoproteins expressed in different CHO cell lines
Citations Over TimeTop 20% of 2016 papers
Abstract
In the biopharmaceutical industry, glycosylation is a critical quality attribute that can modulate the efficacy of a therapeutic glycoprotein. Obtaining a consistent glycoform profile is desired because molecular function can be defined by its carbohydrate structures. Specifically, the fucose content of oligosaccharides in glycoproteins is one of the most important attributes that can significantly affect antibody-dependent cellular cytotoxicity (ADCC) activity. It is therefore important to understand the fucosylation pathway and be able to control fucosylation at the desired level to match predecessor materials in late stage and biosimilar programs. Several strategies were explored in this study and mycophenolic acid (MPA) was able to finely modulate the fucose content with the least undesired side effects. However, the response was significantly different between CHO cell lines of different lineages. Further experiments were then performed for a deeper understanding of the mechanism of fucosylation in different CHO cell lines. Results indicated that changes in the intracellular nucleotide involved in fucosylation pathway after MPA treatment are the main cause of the differences in fucosylation level response in different CHO cell lines. Differences in MPA metabolism in the various CHO cell lines directly resulted in different levels of afucosylation measured in antibodies produced by the CHO cell lines. Biotechnol. Bioeng. 2016;113: 2367-2376. © 2016 Wiley Periodicals, Inc.
Related Papers
- → Comparison of cell lines for stable production of fucose‐negative antibodies with enhanced ADCC(2006)113 cited
- → Increased α3‐fucosylation of α1‐acid glycoprotein in patients with congenital disorder of glycosylation type IA (CDG‐Ia)(2001)21 cited
- → Metabolic engineering of CHO cells to prepare glycoproteins(2018)7 cited
- → Abstract B133: SEA technology: A novel strategy for enhancing antibody effector function(2009)
- → IgG glycans and glyco-engineering(2012)